{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:47:15Z","timestamp":1788299235748,"version":"build-2803163510"},"reference-count":46,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007771","name":"\u015al\u0105ski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["KNW-1-048\/N\/8\/K"],"award-info":[{"award-number":["KNW-1-048\/N\/8\/K"]}],"id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Elevated pulmonary vascular resistance (PVR) unresponsive to vasodilator treatment is a marker of heart failure (HF) severity, and an important predictor of poor results of heart transplantation (HT). Objective: We sought to analyze factors associated with ineffectiveness of sildenafil treatment in end-stage HF patients with elevated PVR with particular emphasis placed on tenascin-C (TNC) serum concentrations. Patients and Methods: The study is an analysis of 132 end-stage HF patients referred for HT evaluation in the Cardiology Department between 2015 and 2018. TNC was measured by sandwich enzyme-linked immunosorbent assay (Human TNC, SunRedBio Technology, Shanghai, China). The endpoint was PVR &gt; 3 Wood units after the six-month sildenafil therapy. Results: The median age was 58 years, and 90.2% were men. PVR &gt;3 Wood units after 6 months of sildenafil treatment were found in 36.6% patients. The multivariable logistic regression analysis confirmed that TNC (OR = 1.004 (1.002\u20131.006), p = 0.0003), fibrinogen (OR= 1.019 (1.005\u20131.033), p = 0.085), creatinine (OR =1.025 (1.004\u20131.047), p = 0.0223) and right ventricular end-diastolic dimension (RVEDd) (OR = 1.279 (1.074\u20131.525), p = 0.0059) were independently associated with resistance to sildenafil treatment. Area under the ROC curves indicated an acceptable power of TNC (0.9680 (0.9444\u20130.9916)), fibrinogen (0.8187 (0.7456\u20130.8917)) and RVEDd (0.7577 (0.6723\u20130.8431)), as well as poor strength of creatinine (0.6025 (0.4981\u20130.7070)) for ineffectiveness of sildenafil treatment. Conclusions: Higher concentrations of TNC, fibrinogen and creatinine, as well as a larger RVEDd are independently associated with the ineffectiveness of sildenafil treatment. TNC has the strongest predictive power, sensitivity and specificity for evaluation of resistance to sildenafil treatment.<\/jats:p>","DOI":"10.3390\/jcm9113539","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T19:51:31Z","timestamp":1604346691000},"page":"3539","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Factors Associated with Ineffectiveness of Sildenafil Treatment in Patients with End-Stage Heart Failure and Elevated Pulmonary Vascular Resistance"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9736-422X","authenticated-orcid":false,"given":"Wioletta","family":"Szczurek","sequence":"first","affiliation":[{"name":"Silesian Center for Heart Diseases in Zabrze, 41-800 Zabrze, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"G\u0105sior","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3410-7407","authenticated-orcid":false,"given":"Micha\u0142","family":"Skrzypek","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health in Bytom, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2555-8102","authenticated-orcid":false,"given":"Ewa","family":"Romuk","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, School of Medicine with the Division of Dentistry, Medical University of Silesia, 41-800 Zabrze, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo\u017cena","family":"Szygu\u0142a-Jurkiewicz","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pul-monary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Associa-tion for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"46","author":"Galie","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.ejheart.2004.10.021","article-title":"Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure","volume":"7","author":"Delgado","year":"2005","journal-title":"Eur. J. Heart Fail."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1161\/01.CIR.102.14.1718","article-title":"Secondary pulmonary hypertension in chronic heart failure: The role of the endothelium in pathophysiology and management","volume":"102","author":"Moraes","year":"2000","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nrcardio.2010.144","article-title":"Pulmonary hypertension with left-sided heart disease","volume":"7","author":"Guazzi","year":"2010","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cjca.2011.09.018","article-title":"Hemodynamic and Clinical Benefits Associated with Chronic Sildenafil Therapy in Advanced Heart Failure: Experience of the Montr\u00e9al Heart Institute","volume":"28","author":"Potter","year":"2012","journal-title":"Can. J. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0008-6363(03)00290-6","article-title":"Lung structural remodeling and pulmonary hypertension after myocardial infarction: Complete reversal with irbesartan","volume":"58","author":"Jasmin","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.107.716373","article-title":"Sildenafil Improves Exercise Capacity and Quality of Life in Patients with Systolic Heart Failure and Secondary Pulmonary Hypertension","volume":"116","author":"Lewis","year":"2007","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.healun.2009.04.013","article-title":"Acute Hemodynamic Effects of Intravenous Sildenafil Citrate in Congestive Heart Failure: Comparison of Phosphodiesterase Type-3 and -5 Inhibition","volume":"28","author":"Botha","year":"2009","journal-title":"J. Heart Lung Transpl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2174\/157016109789043955","article-title":"The impact of pharmacotherapy on the cardiopulmonary exercise test response in patients with heart failure: A mini review","volume":"7","author":"Guazzi","year":"2009","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_10","first-page":"116","article-title":"Impact of sublingual sildenafil on pulmonary hypertension in patients with heart failure","volume":"92","author":"Freitas","year":"2009","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijcard.2008.04.061","article-title":"Six months of sildenafil therapy improves heart rate recov-ery in patients with heart failure","volume":"136","author":"Guazzi","year":"2009","journal-title":"Int. J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijcard.2009.03.041","article-title":"Ventilatory efficiency and dyspnea on exertion improvements are related to reduced pulmonary pressure in heart failure patients receiving Sildenafil","volume":"144","author":"Guazzi","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.14740\/jocmr3008w","article-title":"Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients with Heart Failure with Reduced Left Ventricular Ejection Fraction: A Meta-Analysis","volume":"9","author":"Cesaro","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.jacc.2007.07.078","article-title":"Long-Term Use of Sildenafil in the Therapeutic Management of Heart Failure","volume":"50","author":"Guazzi","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","first-page":"14202","article-title":"The pathogenesis of pulmonary hypertension\u2014An update","volume":"145","author":"Huber","year":"2015","journal-title":"Swiss Med. Wkly."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2310\/JIM.0b013e3182880c11","article-title":"Tenascin-C as Predictor of Left Ventricular Remodeling and Mortality in Patients with Dilated Cardiomyopathy","volume":"61","author":"Sarli","year":"2013","journal-title":"J. Investig. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10735-010-9260-z","article-title":"Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: Implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies","volume":"41","author":"Franz","year":"2010","journal-title":"J. Mol. Histol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0735-1097(00)01117-7","article-title":"Adventitial remodeling after angioplasty is associated with expres-sion of tenascin mRNA by adventitial myofibroblasts","volume":"37","author":"Wallner","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1253\/circj.71.327","article-title":"Higher Serum Tenascin-C Levels Reflect the Severity of Heart Failure, Left Ventricular Dysfunction and Remodeling in Patients with Dilated Cardiomyopathy","volume":"71","author":"Terasaki","year":"2007","journal-title":"Circ. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1152\/ajplung.00119.2006","article-title":"Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension","volume":"291","author":"Mckean","year":"2006","journal-title":"Am. J. Physiol. Cell. Mol. Physiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.7754\/Clin.Lab.2013.130702","article-title":"Serum levels of tenscin-C variants in congestive heart failure patients: Comparative analysis of ischemic, dilated, and hypertensive cardiomyopathy","volume":"60","author":"Franz","year":"2014","journal-title":"Clin. Lab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00395-009-0017-3","article-title":"Time course and mechanisms of left ventricular systolic and diastolic dysfunction in monocrotaline-induced pulmonary hypertension","volume":"104","author":"Gillebert","year":"2009","journal-title":"Basic Res. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"213S","DOI":"10.1378\/chest.114.3_Supplement.213S","article-title":"Elastase and the pathobiology of unexplained pulmonary hypertension","volume":"114","author":"Rabinovitch","year":"1998","journal-title":"Chest"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1152\/ajplung.00171.2001","article-title":"Altered hemodynamics controls matrix metalloproteinase ac-tivity and tenascin-C expression in neonatal pig lung","volume":"282","author":"Jones","year":"2002","journal-title":"Am. J. Physiol. Lung. Cell Mol. Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1164\/rccm.200502-296OC","article-title":"Inhaled Iloprost Reverses Vascular Remodeling in Chronic Experimental Pulmonary Hypertension","volume":"172","author":"Schermuly","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Rohm, I., Gr\u00fcn, K., M\u00fcller, L.M., Kretzschmar, D., Fritzenwanger, M., Yilmaz, A., Lauten, A., Jung, C., Schulze, P.C., and Berndt, A. (2017). Increased Serum Levels of Fetal Tenascin-C Variants in Patients with Pulmonary Hypertension: Novel Biomarkers Reflecting Vascular Remodeling and Right Ventricular Dysfunction?. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112371"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.cardfail.2009.06.443","article-title":"Incremental Prognostic Values of Serum Tenascin-C Levels With Blood B-type Natriuretic Peptide Testing at Discharge in Patients With Dilated Cardiomyopathy and Decompensated Heart Failure","volume":"15","author":"Fujimoto","year":"2009","journal-title":"J. Card. Fail."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3109\/1354750X.2010.492431","article-title":"Circulating biomarkers of tissue remodelling in pulmonary hy-pertension","volume":"15","author":"Schumann","year":"2010","journal-title":"Biomarkers"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1055\/s-0038-1648479","article-title":"Blood Viscosity and Cardiovascular Disease","volume":"67","author":"Lowe","year":"1992","journal-title":"Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0021-9150(86)90121-8","article-title":"Cardiovascular risk factors and hemorheology. Physical fitness, stress and obesity","volume":"59","author":"Ernst","year":"1986","journal-title":"Atherosclerosis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0021-9150(92)90234-8","article-title":"The possible role of hemorheology in atherothrombogenesis","volume":"94","author":"Koenig","year":"1992","journal-title":"Atherosclerosis"},{"key":"ref_32","first-page":"591","article-title":"CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells","volume":"391","author":"Henn","year":"1998","journal-title":"Nat. Cell Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/01.ATV.10.2.263","article-title":"Fate of fibrinogen in human arterial intima","volume":"10","author":"Smith","year":"1990","journal-title":"Arteriosclerosis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1152\/ajpcell.00515.2008","article-title":"Fibrinogen-induced endothelin-1 production from endothelial cells","volume":"296","author":"Sen","year":"2009","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.transproceed.2020.01.103","article-title":"Modified Model for End-Stage Liver Disease Is an Indicator of the Ineffectiveness of Sildenafil Treatment in Patients with Advanced Heart Failure and Increased Pulmonary Vascular Resistance","volume":"52","author":"Szczurek","year":"2020","journal-title":"Transpl. Proc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2215\/CJN.10191013","article-title":"Presence and Outcomes of Kidney Disease in Patients with Pulmonary Hypertension","volume":"9","author":"Navaneethan","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCHEARTFAILURE.110.958801","article-title":"Clinical Characteristics of Pulmonary Hypertension in Patients with Heart Failure and Preserved Ejection Fraction","volume":"4","author":"Thenappan","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2008.05.068","article-title":"Importance of venous congestion for worsening of renal func-tion in advanced decompensated heart failure","volume":"53","author":"Mullens","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1086\/690018","article-title":"Kidney dysfunction in patients with pulmonary arterial hyper-tension","volume":"7","author":"Nickel","year":"2017","journal-title":"Pulm Circ."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.cardfail.2012.10.010","article-title":"Congestive Renal Failure: The Pathophysiology and Treatment of Renal Venous Hypertension","volume":"18","author":"Ross","year":"2012","journal-title":"J. Card. Fail."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11897-019-00431-4","article-title":"Pulmonary Hypertension in Advanced Heart Failure: Assessment and Management of the Failing RV and LV","volume":"16","author":"Rao","year":"2019","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0735-1097(00)01102-5","article-title":"Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure","volume":"37","author":"Ghio","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1183\/09059180.00007414","article-title":"The right ventricle in pulmonary arterial hypertension","volume":"23","author":"Naeije","year":"2014","journal-title":"Eur. Respir. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/cvr\/cvx148","article-title":"Treatment strategies for the right heart in pulmonary hypertension","volume":"113","author":"Westerhof","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jacc.2016.10.047","article-title":"The Relationship Between the Right Ventricle and its Load in Pulmonary Hypertension","volume":"69","author":"Noordegraaf","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2045894019845611","DOI":"10.1177\/2045894019845611","article-title":"Right Heart in Pulmonary Hypertension: From Adaptation to Failure","volume":"9","author":"Ren","year":"2019","journal-title":"Pulm. Circ."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3539\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:28:17Z","timestamp":1760178497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["jcm9113539"],"URL":"https:\/\/doi.org\/10.3390\/jcm9113539","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]}}}